NEW YORK – Pfizer lost $394 million in the fourth quarter as it booked billions in charges for layoffs and losses related to the acquisition of a trouble-plagued business that makes sterile injectable medicines.
The world’s biggest drugmaker posted a $12.3 billion profit during the same period a year earlier, when it got a huge boost from the U.S. tax overhaul late that year.
The weak report, the first under new Chief Executive Albert Bourla, overshadowed Pfizer’s impressive streak of getting four new cancer drugs, all likely billion-dollar sellers, approved in the last 14 weeks of 2018.
It’s outlook also left investors wanting.
Pfizer expects full-year earnings in the range of $2.82 to $2.92 per share. Industry analysts have been expecting annual per-share earnings of $3.04.
The company is projecting revenue of between $52 billion and $54 billion, which is also short of the $54.3 billion Wall Street is looking for.
The maker of Viagra and pain treatment Lyrica has been struggling for a couple years to upgrade sterile injectable drug factories it bought from Hospira. Those sites are in such bad shape, repairs have dragged on far longer than Pfizer expected. Production shutdowns have reduced sales and caused lingering nationwide shortages of crucial injected painkillers, antibiotics and other medicines needed by hospitals.
In premarket trading Tuesday, Pfizer shares fell 92 cents, or 2.33 per cent, to $38.50.
The New York company lost 7 cents per share in the latest quarter. But earnings, adjusted for all the one-time charges, amounted to 64 cents per share, one cent more than expected, according to a survey by Zacks Investment Research.
Pfizer Inc. posted revenue of $13.98 billion in the quarter, up 2 per cent. The strong dollar trimmed revenue by 3 per cent, Pfizer said.
Sales of Pfizer’s growing portfolio of cancer drugs jumped 27 per cent to $1.91 billion. Lyrica sales rose 8 per cent to $1.2 billion, and sales of stroke-preventing Eliquis jumped 28 per cent to $910 million.
But sales of top seller Prevnar 13, a vaccine against pneumococcal infections, dipped 1 per cent, to $1.5 billion in the fourth quarter.
Sales of consumer health products such as ChapStick and Centrum vitamins rose 3 per cent to $974 million. Pfizer is forming a joint venture combining that business with GlaxoSmithKline’s consumer business.
“We enter 2019 with confidence in the competitive position of our businesses,” Bourla said in a statement.
Its shares have fallen slightly more than 9 per cent since the beginning of the year, while the Standard & Poor’s 500 index has climbed 5.5 per cent.
Elements of this story were generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research.News from © Canadian Press Enterprises Inc. 2019